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Abstract
Background: The management of patients who develop gastrointestinal (GI) bleeding after
acute myocardial infarction (MI) is difficult due to concerns about possible cardiovascular
complications. Gastroenterologists are often reluctant to perform endoscopic procedures despite
urgent indications. We performed a systematic review of the literature to determine the safety
of endoscopic procedures after MI.
Methods: We searched MEDLINE, EMBASE and the Cochrane Central Register of
Controlled trials for controlled clinical trials or case series examining the diagnostic efficacy
and complications of esophagogastroduodenoscopy (EGD), colonoscopy and flexible sigmo-
idoscopy after MI. Title and abstract screening was followed by full-text review with subsequent
data extraction of included studies.
Results: A total of seven studies met inclusion criteria. Four studies evaluated safety and
efficacy of EGD after MI. The reported complication rate ranged between 1–8%, with a large
predominance of minor complications. We found one study addressing safety of flexible
sigmoidoscopy that reported minor complications in two patients. We also identified one study
addressing the safety of colonoscopy after MI, which showed a complication rate of 9%. Most of
these complications were minor. A decision analysis was also included in this review.
Conclusions: Our review demonstrated that endoscopic procedures are safe and beneficial in
stable patients with GI bleeding after recent MI and should be performed without a requisite
delay. Unstable patients should undergo endoscopic procedures only in the intensive care
setting, after stabilization and with close monitoring. (Cardiol J 2012; 19, 5: 447–452)
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Introduction
Patients with myocardial infarction (MI) may,
in theory, be more susceptible to cardiovascular
complications caused by endoscopic procedures.
Management of patients who develop gastrointes-
tinal (GI) bleeding after acute MI, or patients with
evidence of active GI bleeding at the time of MI is
challenging. Despite urgent indications, gastroen-
terologists may be reluctant to perform endosco-
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pic procedures in patients with acute or recent MI.
In the absence of diagnostic and therapeutic endo-
scopy, standard percutaneous coronary intervention
(PCI) protocols, including anticoagulation or fibri-
nolytic therapy are frequently withheld resulting in
poorer outcomes.
Currently, there are no guidelines to address
these difficult issues. We performed a systematic
review of the safety and efficacy of endoscopic pro-
cedures in the setting of acute or recent MI in or-
der to clarify the risk/benefit ratio and provide pre-
liminary recommendations.
Methods
Study selection
We searched MEDLINE (1950 to March 2012),
EMBASE (1980 to March 2012) and the Cochrane
Central Register of Controlled Trials (inception to
March 2012) using keywords and/or medical sub-
ject headings (MeSH) for MI and endoscopic pro-
cedures. The detailed search strategy can be found
in Table 1. We screened the titles and abstracts of
references identified in our search and those meet-
ing our inclusion criteria were retrieved for full-text
review.
Two investigators (MC and JG) independently
screened titles, abstract and full-texts. To be includ-
ed, a study had to be a clinical trial or case series
(with predefined inclusion study sample size above
20 patients), examining the diagnostic efficacy and
complications of esophagogastroduodenoscopy
(EGD), colonoscopy or flexible sigmoidoscopy with-
in 30 days after MI. References not published in
English were excluded.
Data extraction
We extracted data on the study design, patient
population, endoscopic procedure used, and the size
of the study sample. The primary outcome of inter-
est was development of cardiovascular complica-
tions during or after the endoscopic procedures. In
addition, we examined the efficacy of the endoscopic
procedures in terms of diagnostic yield and impact
on management.
Results
Study flow and characteristics
Our literature search yielded 420 references of
which 25 full text articles were retrieved. Seven
studies [1–7] met our predefined inclusion criteria.
Study characteristics are shown in Table 2. No
randomized controlled trials were identified. Three
studies were controlled clinical trials [1, 3, 4], three
studies did not have control groups [2, 5, 6]  and one
was a decision analysis [7]. The seven studies in-
cluded 1081 patients. All study participants had a dia-
gnosis of GI bleeding (upper or lower) as the indica-
tion for endoscopy. Five studies included patients
undergoing EGD [3–7], one evaluated flexible sig-
moidoscopy [2] and one evaluated colonoscopy [1].
Outcomes
Flexible sigmoidoscopy. Cappell [2] evalu-
ated the risks and benefits of flexible sigmoidosco-
py after MI. This study demonstrated a diagnostic
yield of 37%. Therapeutic benefit was achieved in
9% of patients. Two patients had complications, of
which one was considered minor (asymptomatic
transient bradycardia) and the other one was an MI.
Colonoscopy. A study by the same authors
evaluated the safety and efficacy of colonoscopy
after MI in a controlled trial, the control group in-
cluded patients with GI bleed without history of MI.
The diagnostic yield was similar, 46% in the MI
group and 40% in the control group (p = 0.47).
There was a higher complication rate of 9% (9 pa-
tients) in the MI group vs. 1% (1 patient) in the con-
trol group (p < 0.03). However, 8 of the 9 patients
had minor complications (transient hypotension in
7 patients and transient bradycardia in 1 patient)
which resolved upon conclusion of the procedure.
One major complication was reported (death 14 h
Table 1. Sample search strategy for
OVID MEDLINE.
Phase 1: Search terms for myocardial infarction
1. exp Myocardial Infarction
2. (myocardial adj infarction).mp.
3. exp Acute Coronary Syndrome
4. or/1-3
Phase 2: Search terms for endoscopy
5. exp Endoscopy
6. exp Endoscopy, Gastrointestinal
or exp Endoscopy, Digestive System
7. exp Esophagoscopy
8. exp Gastroscopy
9. exp Duodenoscopy
10. exp Colonoscopy
11. (EGD or endoscopy).mp.
12. or/5-11
Phase 3: Combining the searches and
restricting to English
13. 4 and 12
14. limit 13 to English language
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after colonoscopy) and was not believed by the in-
vestigators to be related to the procedure [1].
Esophagogastroduodenoscopy. Four stud-
ies evaluated the safety and efficacy of EGD after
MI [3–6]. Mumtaz et al. [5] found a diagnostic yield
of 88%. A therapeutic intervention was performed
in 30% of patients at the time of the procedure. The
complication rate was 8% (7 patients), which includ-
ed hypotension (3 patients), bradycardia (2 patients)
and hypoxia (2 patients). There were no procedure
related deaths in the study.
Cappell and Iacovone [3] studied EGD after MI
in a controlled study; the control group had similar
indications for EGD without MI within 6 months.
The diagnostic yield was 85% in the MI group and
83% in the control group (p = 0.79). There was
a therapeutic benefit in 6% of the MI group patients.
The complication rate was 1.5% (3 patients) in the
control group and 7.5% (15 patients) in the MI
group. Of these, complications in 13 patients were con-
sidered mild and included 11 instances of transient
hypotension and 2 of transient hypoxia. The other
2 complications where major and included 1 fatal
ventricular tachycardia and 1 near respiratory arrest.
Spier et al. [6] demonstrated that the diagnos-
tic yield of EGD was 68.4% associated with a ther-
apeutic benefit in 19.4% of patients. The complica-
tion rate was 1.5% (2 patients who experienced
hypotension, bradycardia and hypoxia). In a sub-
group analysis, there was no increased risk of com-
plications in patients with ST elevation MI (p = 1.0),
patients with depressed left ventricular function
(p = 0.41) or those with elevated troponin levels
(p = 1.0). Six patients had all three risk factors and
did not experience any complications.
Lin et al. [4] evaluated predictors of endosco-
pic therapy in patients with both upper GI bleed and
MI. In this study, groups were divided into patients
Table 2. Study characteristics.
Author, year Study Study Population N Intervention Control
(reference) design objective
Flexible sigmoidoscopy
Cappell, 2004 Uncontrolled Risk vs. benefit Patients 30 day 78 Flexible None
of flexible after MI sigmoido-
sigmoidoscopy scopy
after MI
Colonoscopy
Cappell, 2004 Controlled Risk vs. benefit Patients 30 days 200 Colono- Patients
of colonoscopy after MI scopy having
soon after MI   colonoscopy
without MI
EGD
Cappell, 1999 Controlled Establish safety Patients 400 EGD Patients
and efficacy undergoing EGD having EGD
of EGD after MI   within 30 days without MI
after MI in last 6 months
Lin, 2006 Controlled Predictors Patients with 183 MI after UGIB after MI
of endoscopic UGIB and MI UGIB
therapy in patients (7 days)
with UGIB and MI
Mumtaz, 2007 Uncontrolled Safety and utility Patients 85 EGD None
of EGD  in post-MI undergoing
patients EGD within
4 weeks of MI
Spier, 2007 Uncontrolled Safety and efficacy Patients 135 EGD None
of EGD after MI  undergoing
EGD within
30 days after MI
Decision analysis
Yachimski, 2008 Decision Safety of EGD Patients with 10,000 EGD Direct CATH
analysis prior to CATH in UGIB and MI hypo- before (no EGD)
patients with MI thetical CATH
CATH — cardiac catheterization; EGD — esophagogastroduodenoscopy; MI — myocardial infarction; UGIB — upper gastrointestinal bleeding
450
Cardiology Journal 2012, Vol. 19, No. 5
www.cardiologyjournal.org
presenting with upper GI bleed who then developed
an MI (GI bleed group) and patients presenting with
MI who subsequently developed upper GI bleed (MI
group). The diagnostic yield of EGD in both groups
was similar — 78% in the GI bleed group and 80%
in the MI group (p = NS). The therapeutic efficacy
of EGD was 41% in the GI bleed group and 17% in
the MI group (p < 0.01). Only severe complication
rates were reported and were 1% in each group.
Decision analysis. Yachimski et al. [7] created
a decision analytic model from a hypothetical cohort
of 10,000 patients. Using decision analysis, patients
with upper gastrointestinal bleeding (UGIB) and
acute MI were assigned to one of two strategies:
(1) EGD prior to cardiac catheterization (EGD strat-
egy) and (2) cardiac catheterization without EGD
(CATH strategy). In patients with overt UGIB, the
EGD strategy resulted in 97 deaths per 10,000 pa-
tients, compared with 600 deaths per 10,000 pa-
tients with the CATH strategy. The EGD strategy
also resulted in fewer non-fatal complications (1,271
vs. 6,000 per 10,000 patients). Conversely, in pa-
tients with occult GI bleeding, the EGD strategy
resulted in more deaths (59 vs. 16 per 10,000 pa-
tients) and more non-fatal complications (888 vs. 160
per 10,000 patients) than the CATH strategy. Pa-
tients were stratified by cardiac risk categories based
on ejection fraction (normal, moderately depressed
or severely depressed), the degree of troponin ele-
vation and STEMI vs. NSTEMI. There was no sta-
tistically significant association of any of these cate-
gories with endoscopy-related complications.
Discussion
The mortality from acute coronary syndromes
has significantly decreased in the last few decades
[8–10]. Most of the improvement in the 30-day post
MI mortality comes from increased use of fibrinolytic
therapy and PCI. Anti-platelet agents (such as aspi-
rin, clopidogrel, prasugrel), glycoprotein IIb/IIIa in-
hibitors, as well as anticoagulation with unfraction-
ated or low molecular weight heparin play an impor-
tant role in peri- and post-PCI therapy. The use of
anti-platelet agents and heparin carries an increased
risk of bleeding. The majority of bleeding occurs at
the site of vascular access [11] but gastrointestinal
bleeding also takes place. Approximately 2% of pa-
tients undergoing PCI experience GI bleeding [11,
12]. GI bleeding following PCI prolongs hospital stay
and carries increased mortality risk [12].
Endoscopy plays a major role in the diagnosis
and therapy of GI bleeding. Endoscopic procedures,
in general, are considered to be very safe and well
tolerated with a very low complication rate in gen-
eral population [13–15]. Mild complications in the
form of alterations in heart rate, blood pressure,
oxygen saturation, as well as ST-segment changes
are well known and documented in the literature
[16–25]. Acute and severe cardiovascular compli-
cations in the form of MI, vasovagal reaction, ar-
rhythmias, and congestive heart failure occur very
infrequently during gastrointestinal endoscopy with
an overall incidence of 0.14% [26]. Serious compli-
cations occur exclusively in the setting of known
underlying heart disease. In patients with severe
coronary artery disease peri-procedural ischemia
occurs in 16% of patients [27].
To our knowledge, this is the first systematic
review on the safety of endoscopic procedures af-
ter MI. Our results demonstrated that EGD is safe
and beneficial within one month after MI in relative-
ly stable patients with significant bleeding and
should be performed in these patients without un-
necessary delay. The complication rate of endoscop-
ic procedures after MI ranged from 1–9% with 81%
being considered minor by the original investiga-
tors. All endoscopic complications in patients with
MI were cardiopulmonary. The predominance of
cardiopulmonary complications, as suggested by
Cappell and Iacovone [3], probably occurs because
MI decreases cardiopulmonary reserve but is not
likely to affect the risk of other complications, such
as gastrointestinal perforation or hemorrhage. Car-
diopulmonary complications may also depend more
on general clinical status, whereas other complica-
tions are more affected by the skill of the operator
and the patient’s anatomy [28].
The timing of endoscopy in relation to MI is
likely important in terms of risk. Depending on the
clinical scenario (e.g., hemodynamically significant
vs. non-hypotensive GI bleeding), it may be reason-
able to wait upwards of a week after MI before per-
forming the endoscopy. In the study by Spier et al.
[6], the complication rate of endoscopy performed
on hospital day 0 vs. > 24 h after MI was signifi-
cantly higher (11.8% vs. 0%, respectively, p = 0.02).
The overall 30 day risk was low. Unfortunately,
sicker patients are likely to require endoscopy soon-
er rather than later.
The general consensus on transfusion strate-
gy in patients with coronary artery disease has been
to maintain the hemoglobin level > 10 g. A recent-
ly published randomized controlled trial was the
first to compare transfusion strategies in patients
with acute MI. This trial showed that a transfusion
threshold of hemoglobin < 10 g was associated with
a significantly increased risk of death, recurrent MI
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or new or worsening congestive heart failure com-
pared with a transfusion threshold of hemoglobin
< 8 g [29]. Thus, the benefits of prompt transfu-
sion and urgent diagnostic/therapeutic intervention
should be carefully weighed against the risks.
Patients with MI who develop GI bleeding are
often on antiplatelet agents for primary or second-
ary prophylaxis. Current guidelines state that the
decision to discontinue antiplatelet agents in the
setting of an acute GI bleed should be made on an
individual basis, and these drugs should be restart-
ed as soon as the risk for cardiac events is thought
to outweigh the risk of bleeding [30].
A review of the safety of endoscopic procedures
such endoscopic retrograde cholangiopancreatogra-
phy (ERCP) and endoscopic ultrasound was beyond
the scope of our review due to their elective nature
and available alternatives which may be less inva-
sive and risky. However, it has been shown in the
literature that ERCP also carries acceptable risks
when performed soon after acute coronary syn-
drome [31].
Our review is limited by the small number of
included studies. We found no randomized con-
trolled studies and the numbers of patients in the
included studies are small. Future research should
focus on larger cohort studies and possibly prospec-
tive, randomized controlled trials, although the lat-
ter may be difficult to perform.
Conclusions
Our review suggests that relatively stable pa-
tients with significant bleeding or other strong in-
dications for endoscopy should undergo the proce-
dure even in the event of a recent or active MI. Such
patients should have the procedure performed with
electrocardiographic, blood pressure, and pulse-
oximetry monitoring. Clinically unstable patients
with hypoxia, hypotension, life-threatening arrhyth-
mias, or angina are at an increased risk of cardio-
vascular complications from endoscopic procedures.
Such patients might also undergo the procedure in
an intensive care setting and after clinical stabili-
zation. This may require transfusion of red blood
cells in the case of severe blood loss, treatment of
underlying cardiac conditions (such as decompen-
sated heart failure, arrythmias etc.) or endotrache-
al intubation with mechanical ventilation [3].
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